Firefighters are at increased risk of death from heart attacks when compared to other emergencyy service professionals whose jobs involve similar components such as emergency call-outs and shift work. In the largest analysis of cause of death amongst on-duty firefighters, firefighter deaths were classified according to the duty performed during the onset of symptoms or immediately prior to any sudden death. The majority of deaths due to a cardiovascular cause (i.e. heart attack) occurred during fire suppression whilst this activity represented a relatively small amount of a firefighters professional time. There was also a risk of death associated with other duties such as emergency non-fire response and physical exertion. The investigators hypothesize that participation in active fire-fighting duties impairs blood vessel function and increases blood clot formation when compared with non-fire-fighting activities. In this study, healthy career firefighters will be assessed after three periods of duty: fire-suppression, emergency response without fire suppression and following a sedentary shift. The investigators will take blood samples to measure platelet activity (platelets are the particles in blood that help blood clot) and will examine how blood clots outside of the body. The investigators will then perform studies placing small needles in the arm to assess blood vessel function following these duties. By undertaking this comprehensive assessment of blood, blood vessel and heart function the investigators hope to understand the mechanisms whereby the risk of a heart attack, fatal or otherwise, is posed throughout these distinct duties that firefighters undertake on a daily basis.
Full Title of Study: “Effect of Fire Suppression and Emergency Duties on Vascular Function in Firefighters”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 2014
- Procedure: Forearm Vascular Study
- Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
- Procedure: Badimon Chamber
- Ex-vivo assessment of thrombus formation using the Badimon Chamber
Arms, Groups and Cohorts
- Fire suppression
- Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
- Non-fire emergency duty
- Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
- Sedentary shift
- Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
Clinical Trial Outcome Measures
- Forearm blood flow measured by venous occlusion plethysmography in response to infused vasodilators
- Time Frame: up to 12 hours after exposure
- Ex-vivo thrombus formation using the Badimon chamber
- Time Frame: up to 12 hours after exposure
- Plasma t-PA and PAI concentrations following infusion of bradykinin
- Time Frame: During forearm study, up to 12 hours after exposure
Participating in This Clinical Trial
- Non-smoking healthy firefighters Exclusion Criteria:
- Current smoker – History of lung or ischaemic heart disease – Malignant arrhythmia – Systolic blood pressure >190mmHg or <100mmHg – Renal or hepatic dysfunction – Previous history of blood dyscrasia – Unable to tolerate the supine position – Blood donation within the last 3 months – Recent respiratory tract infection within the past 4 weeks – Routine medication including aspirin and NSAIDs
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- University of Edinburgh
- Provider of Information About this Clinical Study
- Overall Official(s)
- David E Newby, MD PhD, Study Chair, University of Edinburgh
- Nicholas L Mills, MBChB PhD, Study Director, University of Edinburgh
- Amanda L Hunter, MBChB, Principal Investigator, University of Edinburgh
- Overall Contact(s)
- Amanda L Hunter, MBChB, +441312426437, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.